Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
relugolix + docetaxel
- Development stage
- Phase 1
- Lead developer
- Myovant Sciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Relugolix + docetaxel is a combination regimen used in the treatment of advanced prostate cancer, particularly in the metastatic or high-risk setting. **Relugolix** is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly suppresses testosterone to castrate levels without the testosterone surge associated with GnRH agonists. **Docetaxel** is an intravenous taxane-class cytotoxic chemotherapy agent that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cells, including prostate cancer cells. Used in combination, relugolix provides androgen deprivation therapy (ADT), while docetaxel provides cytotoxic antineoplastic effects. This regimen seeks to maximize cancer control via hormonal and cytotoxic mechanisms.
- Other names
- relugolix plus docetaxelrelugolix and docetaxel
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on relugolix + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on relugolix + docetaxel.